Design Therapeutics, Inc. — Q1 2022 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company developing GeneTAC molecules for diseases caused by inherited nucleotide repeat expansions. This unaudited filing covers the three months ended March 31, 2022; comparative results are for Q1 2021. The company had no approved products and generated no product revenue.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 / prior balance |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $8.8 million | $3.9 million |
| General and administrative expense | $4.6 million | $1.8 million |
| Total operating expenses | $13.4 million | $5.7 million |
| Net loss | $13.3 million | $5.5 million |
| Net loss per share, basic and diluted | $0.24 | $0.31 |
| Net cash used in operating activities | $11.8 million | $3.7 million |
| Cash and cash equivalents, March 31 | $287.3 million | $298.6 million at Dec. 31, 2021 |
| Investment securities, March 31 | $83.9 million | $85.5 million at Dec. 31, 2021 |
Cash, cash equivalents and investment securities totaled $371.2 million at quarter-end. Current assets were $373.9 million versus current liabilities of $5.5 million. There was no revenue or meaningful operating margin to report. No borrowing debt balance is disclosed; liabilities include related-party operating lease obligations, with $3.5 million of lease liabilities shown in the maturity schedule.
Changes versus the prior comparable period
- Operating expenses increased $7.7 million year over year. R&D rose $4.9 million, primarily reflecting expanded FA clinical development and DM1 and FECD programs, increased personnel, and higher stock-based compensation. G&A rose $2.8 million, principally due to personnel, public-company costs, insurance and professional fees.
- Net loss increased $7.8 million. Weighted-average shares rose to 55.5 million from 17.6 million, reflecting the 2021 IPO and preferred-stock conversion; this contributed to lower loss per share despite the larger total loss.
- Operating cash use increased $8.1 million. Q1 2021 investing and financing inflows were unusually high due largely to securities maturities and the IPO and preferred financing; Q1 2022 financing cash flow was only $0.2 million.
- Available-for-sale securities had $1.1 million of unrealized losses in Q1 2022, recorded in other comprehensive loss. The company attributed declines primarily to interest-rate changes and recorded no credit-loss allowance.
Outlook, management commentary and notable items
- The FDA cleared the IND for lead FA candidate DT-216 in February 2022. The company completed dosing in the first single-ascending-dose cohort of its Phase 1 trial in March, received Fast Track designation, and expected initial topline data in the second half of 2022.
- For DM1, the company expected to complete IND-enabling studies and seek regulatory clearance for a first-in-human trial in 2023. It planned further preclinical work on FECD.
- Management expected losses and expenses to increase as it advances development, expands capabilities and supports public-company operations. It stated that available cash and cash equivalents were sufficient for anticipated cash requirements for more than 12 months after the financial statements were issued, but that additional financing would be needed to take candidates through regulatory approval and commercialization.
- The company paid $0.1 million to WARF upon IND acceptance and may owe up to $17.5 million in additional regulatory and commercial milestones, plus low-single-digit royalties on net sales and other potential license payments.
- In March, the company amended a lease with an executive chairperson-affiliated entity for approximately 4,900 additional square feet; delivery was expected in Q3 2022. The existing related-party lease covers approximately 12,370 square feet and runs through 2027.
- Key risks include clinical and regulatory uncertainty, dependence on third-party manufacturers and research organizations, possible development delays or adverse effects, need for future capital, competition, intellectual-property challenges, and potential effects of COVID-19, inflation, supply constraints and geopolitical events. The company reported no material litigation, contingent liabilities or off-balance-sheet arrangements.
Important facts for investors to verify
- Whether DT-216 trial progress and the expected second-half 2022 topline timing were achieved, and how to interpret preliminary versus final data.
- Whether the stated cash runway assumptions remain valid as clinical, manufacturing, staffing and facility spending increases.
- Future clinical milestones, costs and financing needs for DT-216, DM1 and FECD, including whether DM1 IND-enabling work remains on schedule.
- The terms and potential costs of the related-party lease expansion and WARF milestones, royalties and sublicense obligations.
- Potential dilution from future financing and equity awards; 55,618,326 common shares were outstanding at March 31, 2022, and 55,782,448 at May 2, 2022.